These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25434840)

  • 21. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?
    Myatt L; Clifton RG; Roberts JM; Spong CY; Wapner RJ; Thorp JM; Mercer BM; Peaceman AM; Ramin SM; Carpenter MW; Sciscione A; Tolosa JE; Saade G; Sorokin Y; Anderson GD;
    BJOG; 2013 Sep; 120(10):1183-91. PubMed ID: 23331974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.
    Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R
    Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.
    Holmes VA; Young IS; Patterson CC; Maresh MJ; Pearson DW; Walker JD; McCance DR;
    Diabetes Care; 2013 Nov; 36(11):3671-7. PubMed ID: 23920083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Prognostic Value of Angiogenic Markers in Twin Pregnancies to Predict Delivery Due to Maternal Complications of Preeclampsia.
    Binder J; Palmrich P; Pateisky P; Kalafat E; Kuessel L; Zeisler H; Munkhbaatar M; Windsperger K; Thilaganathan B; Khalil A
    Hypertension; 2020 Jul; 76(1):176-183. PubMed ID: 32450740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
    Kusanovic JP; Romero R; Chaiworapongsa T; Erez O; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gotsch F; Edwin SS; Gomez R; Yeo L; Conde-Agudelo A; Hassan SS
    J Matern Fetal Neonatal Med; 2009 Nov; 22(11):1021-38. PubMed ID: 19900040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal angiogenic profile in pregnancies that remain normotensive.
    Faupel-Badger JM; Staff AC; Thadhani R; Powe CE; Potischman N; Hoover RN; Troisi R
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):189-93. PubMed ID: 21641103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
    Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
    PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
    Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
    Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
    Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of angiogenic factors by regular and acute exercise during pregnancy.
    Weissgerber TL; Davies GA; Roberts JM
    J Appl Physiol (1985); 2010 May; 108(5):1217-23. PubMed ID: 20224004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.